Does Microglial Activation Promote Lesion Growth and Progression Among Multiple Sclerosis Patients

NCT04625049 | Enrolling By Invitation

• 1 other identifier: FUP-MS
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess whether increased microglial activation (measured using TSPO-PET) at lesion rim is associated with more rapid lesion growth during 10 year follow up.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (1)

• Correlation of the lesion volume changes to the microglial activity at the initial positron emission tomography imaging

  Correlation of the lesion volume changes in the magnetic resonance imaging to the microglial activity at the initial PET imaging

  Baseline (initial PET), 3, 5, 7 and 10 years

Secondary Outcomes (2)

• magnetic resonance imaging metrics

  Baseline (initial PET), 3, 5, 7 and 10 years

• Multiple Sclerosis Composite Score

  Baseline (initial positron emission tomography), 3, 5, 7 and 10 years

Eligibility Criteria

• Age: 30 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The research will recruit MS-patients who have taken part to our previous PET-imaging MS studies in Turku PET centre. The research interventions will consist of MRI scans, blood sampling, clinical neurological evaluation and patient-reported outcome measures (filling forms).

You may qualify if:

• Participation to a previous PET imaging study of Airas group
• MS diagnosis

You may not qualify if:

• Patients with other neurodegenerative disease than MS
• Contraindication to MR scan investigations
• Patients with claustrophobia, or a history of moderate to severe anxiety disorder or panic attacks (which could potentially lead to preterm termination of the imaging)

Sponsors & Collaborators

• Turku University Hospital: lead

Study Sites (1)

Turku PET Centre

Turku, Southwest Finland, 20520, Finland

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Laura Airas

  Turku University Hospital, Division of Clinical Neurosciences

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 5, 2020
• First Posted: November 12, 2020
• Study Start: April 1, 2021
• Primary Completion (Estimated): November 1, 2030
• Study Completion (Estimated): November 1, 2031
• Last Updated: September 22, 2025

Record last verified: 2025-09

Locations

FI (1)